FDA approves Humira for pediatric Crohn’s disease

The FDA has approved adalimumab (Humira) for achieving and maintaining remission in pediatric patients Crohn’s patients six years or older, according to a Medscape report.

Advertisement

An estimated 38,000 children in the United States have Crohn’s disease, according to the report. The indication of the drug as a pediatric treatment was based on a multicenter, randomized and double-blind phase three study.

Humira, from AbbVie, is designed for patients that do not respond adequately to corticosteroids or immunomodulators.

More articles on gastroenterology:
Mobile screenings for Barrett’s esophagus?
6 things to know about colonoscopy cost & what a reimbursement cut would mean
32 statistics on ASC accounts receivable

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.